Neuroscience

Advancing patient care in neurodegenerative diseases with unmet medical needs

AstraZeneca is committed to discovering and developing compounds to improve patient care in neuroscience.

With a rich heritage and a research and development focus on specific aspects of neurodegenerative diseases, analgesia and psychiatry, AstraZeneca continues to push the boundaries of science in neuroscience in collaboration with other innovative partners across industry and academia. A significant unmet medical need remains in the areas of cognitive disorders, chronic pain and other central nervous system disorders. 

 

Collaboration stories

Partnering with influential organisations to extend the reach of our science to more patients and healthcare providers

Our focus on unmet medical needs

More than 450 million people worldwide are affected by mental, neurological or behavioural problems, and the number is steadily rising.

  • Opioid-induced constipation (OIC)

    OIC is a condition caused by prescription opioid pain medicines. Millions of patients are treated with opioids each year.


  • Alzheimer's disease (AD)

    AD is a fatal illness that causes progressive decline in memory and other aspects of cognition.


Opportunities for collaboration


Kate's story


What we're working on

We are committed to developing novel therapies that advance the science of neurodegenerative diseases and have the potential to provide a positive impact on patients around the world.

        Image: Artistic rendering of BACE enzyme.

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Other (as at 10 November)

Phase 1

Phase 1

  • AZD8108 suicidal ideation
  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • ATM AVI targeted serious bacterial infections
  • AZD3241 multiple system atrophy
  • CXL MRSA
  • MEDI2070 Crohn’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3

Phase 3

  • AZD3293 AMARANTH DAYBREAK-ALZ Early Alzheimer's disease
  • Zavicefta (CAZ AVI) serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • Zavicefta (CAZ AVI) hospital-acquired pneumonia/ ventilator-associated pneumonia
  • Zinforo pneumonia/skin infections
  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)



Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Diprivan propofol
  • EMLA EMLA
  • Movantik/Moventig naloxegol
  • Naropin ropivacaine
  • Seroquel IR quetiapine fumarate
  • Seroquel XR quetiapine fumarate
  • Xylocaine lidocaine
  • Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon zolmitriptan

Resources